Jan 15, 2018 · Through sequencing of 79 spatially distinct regions from 16 early stage tumors, we show that despite low mutation burdens, EGFR -mutant Asian LUADs unexpectedly exhibit a complex genomic...

Malignant pleural effusion (MPE) is associated with poor prognosis in patients with advanced lung adenocarcinoma (LUAD), and abnormal activation of epidermal growth factor receptor (EGFR) plays a crucial role in the development of LUAD.

Jun 11, 2022 · Activating mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) are predictive biomarkers for response to EGFR–tyrosine kinase inhibitor (TKI) therapy in lung adenocarcinoma (LUAD).

Our study offers a detailed characterization of EGFR mutation classes in LUAD, highlighting clinical and molecular differences between common and uncommon mutations and establishing a potential link between smoking and certain uncommon EGFR mutations.

Background: Epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma (LUAD) is the most common subtype among non-small cell lung cancer (NSCLC) and targeted therapies are the primary approach for treatment. However, the development of resistance to therapy and histological transformation into small cell lung cancer (SCLC) present significant challenges.

The use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) as first-line treatment in patients with lung adenocarcinoma (LUAD) harboring EGFR-activating mutations has resulted in a dramatic improvement in the management of the disease.

Oct 2, 2024 · Small-cell lung cancer (SCLC) transformation accounts for 3–14% of resistance in EGFR -TKI relapsed lung adenocarcinomas (LUADs), with unknown molecular mechanisms and optimal treatment...

Background: The prognostic significance of epidermal growth factor receptor (EGFR) mutations in stage I invasive lung adenocarcinoma (LUAD) remains debated. Improving the lung cancer staging system requires further investigation into actionable mutations and their association with survival outcomes.

EGFR mutations, assessing their implications for therapy outcomes. Methods: We analyzed a multi-cohort genomic dataset of 19,163 patients with LUAD (5,212 with EGFR mutations), categorizing mutations into common, uncommon, and compound classes. Patient demographics, mutational sig-natures, and tumor microenvironment factors were

Mar 15, 2025 · EGFR is a gene that is overexpressed or mutated in lung cancer cells and is closely associated with the development, progression, and drug resistance of the disease. Similarly, the mutation of HER2 in lung cancer cells is correlated with tumour aggressiveness and prognosis. ... a ROC curve of the LUAD diagnostic model derived from the TCGA ...